QLife
Qlife's Birmingham PKU clinical trial published with strong results - key milestone toward CE-mark submission and market launch
The Company considers the now clinically validated Egoo PHE System to be a proof of concept for the broader Egoo Health platform and is pursuing similar opportunities in large markets such as heart failure and kidney failure, where key biomarker tests can likewise be transitioned from the laboratory to the home.
"The publication is a significant step for us. The positive outcome and publication of this clinical trial allow us to finalize our CE-mark filing, representing a major milestone for the Company. We are preparing our submission dossier accordingly and plan to submit it to the authorities in the near future," says Thomas Warthoe, CEO of Qlife.
"In addition to being an important milestone for the Company, I am extremely pleased to see a lifelong effort to provide people living with this chronic condition a better tool for daily blood management come to fruition," adds Peter Warthoe, CSO of Qlife.
The article can be found here: https://www.mdpi.com/2072-6643/17/23/3800
About PKU
Currently, there is no self-testing phenylalanine product available on the market. The UK PKU population is estimated at 5,000 individuals, the EU population at 50,000, and the Middle East population at 20,000. With an average usage of one Egoo Phe Test per person per week, the immediate total addressable market for the UK/EU/Middle East region is estimated to exceed SEK 1 billion.
For more information, please contact:
Thomas Warthoe
Chief Executive Officer (CEO)
Phn: +45 21 63 35 34
E-mail: tw@egoo.health
This disclosure contains information that Qlife Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 2025-12-05 11:13 CET
| Datum | 2025-12-05, kl 11:13 |
| Källa | Cision |
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 125 000 sidvisningar och 17 000 unika besökare per månad. Vår discord har 7800 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!